ARTICLE | Emerging Company Profile

Rogne: Penetrating peptides

Rogne developing topical peptide targeting IL-23 for mild to moderate psoriasis

October 20, 2014 7:00 AM UTC

Rogne Bioscience Inc. is developing a topical formulation of a naturally occurring human peptide that inhibits production of inflammatory cytokines to treat mild to moderate psoriasis without the side effects of topical steroids or injectable biologics.

The 90% of psoriasis patients with mild to moderate disease are typically treated with topical steroids or vitamin D. The latter is slow to take effect and has low efficacy. Topical steroids are effective but are used episodically due to side effects such as skin atrophy. Stopping therapy frequently leads to flares...